—
In addition to Professor Dame Sarah Gilbert, the plaque-unveiling ceremony included local Member of Parliament, Darren Henry MP, and leading industry professionals.
Nikki Whitfield, CEO of Upperton Pharma Solutions, said: “This celebration marks another milestone in our incredible growth journey as a business. We are looking forward to officially opening our doors to customers and offering a single site solution for development and GMP manufacturing.”
“It was a pleasure to join Upperton for the grand opening of their new facility”, said Guest of Honour, Professor Dame Sarah Gilbert, Principal Investigator at the Pandemic Sciences Institute, University of Oxford and co-creator of the Oxford/AstraZeneca COVID-19 vaccine.
“During the pandemic we saw the importance of academia and industry working closely together to deliver life-saving vaccines and treatments. Upperton’s expansion into this new site is a great example of the crucial role UK-based pharmaceutical organisations have to play in addressing global health challenges. I look forward to collaborating with Upperton in the future.”
The new facility contains ten GMP manufacturing suites, cutting-edge quality control laboratories, and formulation development capabilities equipped with a pilot plant. The facility empowers Upperton to offer customers a seamless transition from early formulation development to clinical trial supplies from Phase 1 to Phase 3 and niche scale commercial manufacturing all on one site.
The official opening marks another milestone for Upperton following the announcement and ongoing build of a new sterile facility on the same site, for the manufacturing of aseptic and terminally sterilized small volume liquids for parenteral, ocular and pulmonary delivery due for completion at the end of 2024.
About Us: Upperton Pharma Solutions has over 24 years’ experience of delivering science-led, high quality, innovative early drug development solutions to pharmaceutical and biotechnology clients worldwide. Based in Nottingham, UK, Upperton has formulation and analytical development laboratories, alongside a fully equipped GMP manufacturing and Quality Control testing capability and is licensed by the MHRA to manufacture materials for clinical trial supplies. In addition to supporting conventional oral solid dosage form development, Upperton has a strong history in spray drying which is applied to address both the challenges with poorly soluble molecules and as a particle engineering technology for targeted deposition for pulmonary and nasal drug products. The company employs around 90 highly skilled personnel and has its headquarters in Nottingham, UK.
Contact Info:
Name: Rob Halliwell
Email: Send Email
Organization: Upperton Pharma Solutions
Website: https://upperton.com
Release ID: 89125140
Google
RSS